EPISODE · Dec 19, 2022 · 15 MIN
Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL
from IMPACT Medicom · host IMPACT Medicom
Live From ASH, New Orleans:In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans. Our Guest:Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Embed this episode
What this episode covers
Live From ASH, New Orleans: In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans. Our Guest: Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode,...
NOW PLAYING
Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.